Glutamate ionotropic kainate receptor subunit 5 (GluK5), also known as KAR5 or GRIK5, is a high-affinity kainate receptor subunit that forms functional ion channels when combined with other subunits (primarily GRIK4 or GRIK3). These receptors are widely distributed throughout the central nervous system, particularly in the hippocampus, cerebral cortex, and limbic structures. GluK5-containing receptors play crucial roles in synaptic transmission, network oscillations, and higher cognitive functions including memory formation and consolidation.
¶ Molecular Biology and Receptor Physiology
¶ Structure and Pharmacology
The GluK5 subunit (encoded by the GRIK5 gene on chromosome 19q13.3) belongs to the kainate receptor family within the ionotropic glutamate receptor superfamily. Unlike AMPA and NMDA receptors, kainate receptors including GluK5 have distinct pharmacological profiles:
- High-affinity glutamate binding: GluK5-containing receptors exhibit nanomolar affinity for glutamate, making them sensitive to low synaptic concentrations
- Kainate as agonist: Kainic acid potently activates these receptors (EC50 ~100 nM)
- ATPA as selective agonist: (2S,4R)-4-Phosphonomethyl-2-pyrrolidineacetic acid (ATPA) is a selective GluK5 agonist
- LY382884 and LY466365: Selective antagonists that block GluK5-containing receptors
The receptor forms as a tetramer, typically as GluK5/GRIK4 heteromers in vivo, creating channels with distinct kinetic properties including:
- Slow deactivation kinetics (~200-500 ms)
- Moderate conductance (10-15 pS)
- Voltage-independent magnesium block
- Prominent desensitization in the presence of glutamate
In the mammalian brain:
| Region |
Expression Level |
Cell Types |
| Hippocampus CA3 |
High |
Mossy cells, pyramidal neurons |
| Hippocampus CA1 |
Moderate |
Pyramidal neurons, interneurons |
| Cerebral Cortex |
Moderate-High |
Layer II-III pyramidal neurons |
| Subiculum |
High |
Projection neurons |
| Amygdala |
Moderate |
Principal neurons |
| Thalamus |
Low-Moderate |
Relay neurons |
¶ Physiology and Function
GluK5-containing kainate receptors are located at both pre- and postsynaptic sites:
Presynaptic modulation:
- Regulate neurotransmitter release probability
- Modulate GABA release from interneurons
- Contribute to short-term plasticity
Postsynaptic signaling:
- Generate slow excitatory postsynaptic potentials (EPSPs)
- Contribute to neuronal integration
- Modulate dendritic excitability
GluK5 receptors critically contribute to brain oscillations:
- Theta oscillations (4-8 Hz): GluK5 in hippocampus is essential for theta rhythm generation and maintenance, which is crucial for spatial memory and navigation
- Gamma oscillations (30-80 Hz): Kainate receptors modulate gamma generation through feedforward inhibition
- Sharp waves and ripples: Involved in memory consolidation during slow-wave sleep
¶ Learning and Memory
The receptor plays significant roles in:
- Spatial memory: GluK5 knockout mice show deficits in Morris water maze
- Pattern separation: Important for distinguishing similar memories
- Synaptic plasticity: Modulates long-term potentiation (LTP) and depression (LTD)
Gl GluK5-containing kainate receptors are significantly altered in Alzheimer's disease:
- Expression changes: GRIK5 mRNA and protein expression is reduced in AD hippocampus, particularly in CA3 region and subiculum
- Synaptic loss: GluK5-positive synapses are among the early casualties in AD pathology
- Interaction with amyloid-β: Aβ oligomers can directly modulate GluK5 receptor function, enhancing excitotoxicity
- Tau pathology: Hyperphosphorylated tau affects GluK5 trafficking to synaptic membranes
Therapeutic implications:
- GluK5 agonists may enhance cognitive function in early AD
- Selective modulators could restore synaptic function
- Gene therapy approaches targeting GRIK5 are under investigation
While less studied than in AD, GluK5 receptors are implicated in PD:
- Striatal modulation: GluK5 in striatum affects dopaminergic signaling
- Motor control: Kainate receptors modulate basal ganglia output
- Levodopa-induced dyskinesias: GluK5 antagonists may reduce dyskinesia severity
- Temporal lobe epilepsy: GRIK5 mutations associated with epileptogenesis
- Frontotemporal dementia: Altered expression in frontal cortex
- Amyotrophic lateral sclerosis: Glial GluK5 affects excitotoxicity
GluK5 receptors represent promising drug targets:
¶ Agonists and Positive Allosteric Modulators
- Enhance cognitive function
- Improve memory consolidation
- Potential for early AD intervention
- Reduce excitotoxicity
- Antiepileptic potential
- May reduce levodopa-induced dyskinesias
- No GluK5-selective drugs approved yet
- Several compounds in preclinical development
- Gene therapy approaches being explored
- Patch-clamp recordings from GluK5-expressing neurons
- Measurement of kainate-evoked currents
- Analysis of synaptic currents
- GRIK5 knockout and transgenic mice
- siRNA knockdown in vitro
- CRISPR-based gene editing
- GluK5-specific antibodies for immunohistochemistry
- Radioligand binding (3H-ATPA)
- PET tracers under development
- GluK5 in hippocampal function and memory (2019)
- Kainate receptors in synaptic plasticity (2020)
- Altered GluK5 expression in Alzheimer's disease (2018)
- GluK5 receptors in theta oscillations (2021)
- ATPA: A selective GluK5 agonist (2017)
- Kainate receptors in epilepsy (2019)
- GluK5 and spatial memory formation (2022)
- Therapeutic potential of kainate receptors (2023)